Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Public ClinicalTrials.gov record NCT02019758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response. Participants: A total of up to 200 16-80 year old patients with a new diagnosis of eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a target of 122 randomized. Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will generate data for all three Aims
Study identification
- NCT ID
- NCT02019758
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Interventions
- Oral Viscous Budesonide Drug
- Fluticasone MDI Drug
- Placebo slurry Drug
- Placebo inhaler Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2014
- Primary completion
- Apr 30, 2018
- Completion
- Mar 31, 2019
- Last update posted
- Apr 26, 2020
2015 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of North Carolina, Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Eosinophilic Esophagitis trials
Other public records listing Eosinophilic Esophagitis. Sorted by last update posted; newest first. Not a recommendation.
- NCT03980886: Characteristics and Inflammatory Markers in Children With Eosinophilic Esophagitis (EoE) Recruiting
- NCT05176262: A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis Active, not recruiting
- NCT05176249: Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population Active, not recruiting
- NCT05083156: Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis Active, not recruiting
- NCT03822325: Inflammatory Mediators as Potential Non-Invasive Biomarkers in Subjects With Eosinophilic Esophagitis Active, not recruiting
- NCT07027826: The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02019758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02019758 live on ClinicalTrials.gov.